AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18396848 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for early childhood educators and children
Number of subjects: 278
Study 18396848 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 278
Study 17240781 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 70% VO2max
Number of subjects: 8
Study 17240781 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise at 30% VO2max
Number of subjects: 8
Study 17240781 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise at 50% VO2max
Number of subjects: 8
Study 17240781 — intervention group
Group type: COMPARATOR
Intervention: Resting experiment
Number of subjects: 8
Study 14663900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbilact infusion (twice a day for 4 days postoperatively)
Number of subjects: 12
Study 10779832 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe closed head injury (CHI) subjects
Number of subjects: 0
Study 10779832 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 10779832 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in more demanding situations
Number of subjects: 0
Study 10779832 — intervention group
Group type: COMPARATOR
Intervention: Controls tested in a random presentation
Number of subjects: 0
Study 8657096 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent insufficient sleep (PIS)
Number of subjects: 600
Study 8657096 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent insufficient sleep (PIS) without sleeping difficulties
Number of subjects: 600
Study 8657096 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent insufficient sleep (PIS) with concomitant sleep complaints
Number of subjects: 600
Study 8657096 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent insufficient sleep (PIS) without sleep complaints
Number of subjects: 600
Study 1387972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepaccine‐B vaccine (3 micrograms) at schedules of 0, 2, 6, 12 months
Number of subjects: 182
Study 1387972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepaccine‐B vaccine (3 micrograms) at schedules of 0, 1, 6, 12 months
Number of subjects: 182
Study 1387972 — intervention group
Group type: COMPARATOR
Intervention: Hepaccine‐B vaccine (3 micrograms) at schedule of 0, 1, 2, 9 months
Number of subjects: 182
Study 1387972 — intervention group
Group type: COMPARATOR
Intervention: Hevac‐B Pasteur vaccine (5 micrograms) at schedule of 0, 1, 2, 9 months
Number of subjects: 182
Study 3885084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato-bismuthate tablet
Number of subjects: 35
Study 3885084 — intervention group
Group type: COMPARATOR
Intervention: Tripotassium dicitrato-bismuthate liquid
Number of subjects: 35
Study 30100404 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anti-reflux surgery
Number of subjects: 58
Study 30100404 — intervention group
Group type: COMPARATOR
Intervention: No surgery (control)
Number of subjects: 58
Study 29927206 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone drains (Group A, n = 19)
Number of subjects: 38
Study 29927206 — intervention group
Group type: COMPARATOR
Intervention: No soft silicone drains (Group B, n = 19)
Number of subjects: 38
Study 29927206 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone drains (Group A)
Number of subjects: 38
Study 29927206 — intervention group
Group type: COMPARATOR
Intervention: No soft silicone drains (Group B)
Number of subjects: 38
Study 24712563 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human GIP infusion with sitagliptin (inhibition of dipeptidyl peptidase 4)
Number of subjects: 24
Study 24712563 — intervention group
Group type: COMPARATOR
Intervention: Synthetic human GIP infusion with placebo
Number of subjects: 24
Study 24712563 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human GLP‐1 infusion with sitagliptin (inhibition of dipeptidyl peptidase 4)
Number of subjects: 24
Study 24712563 — intervention group
Group type: COMPARATOR
Intervention: Synthetic human GLP‐1 infusion with placebo
Number of subjects: 24
Study 23039985 — intervention group
Group type: COMPARATOR
Intervention: All-milk protein milk replacer
Number of subjects: 6
Study 23039985 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glucose high-bicarbonate OAE (without glycine)
Number of subjects: 6
Study 23039985 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glucose high-bicarbonate OAE (with glycine)
Number of subjects: 6
Study 23039985 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glucose OAE containing acetate and propionate
Number of subjects: 6
Study 20163842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 1056
Study 20163842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 1056
Study 20163842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 1056
Study 20163842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 1056
Study 20163842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1056
Study 18391638 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (4 weeks duration)
Number of subjects: 34
Study 17995906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive depletion condition (modified Stroop task)
Number of subjects: 49
Study 17995906 — intervention group
Group type: COMPARATOR
Intervention: Control (color word) group
Number of subjects: 49
Study 15571444 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative group earned incentives for a 50% decrease in urine benzoylecgonine concentrations
Number of subjects: 42
Study 15571444 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative group earned incentives for providing urines with concentrations <300 ng/ml
Number of subjects: 42
Study 15571444 — intervention group
Group type: COMPARATOR
Intervention: Control group encouraged to abstain under the same schedule
Number of subjects: 42
Study 11421506 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 9 microg
Number of subjects: 0
Study 11421506 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline Turbuhaler 0.5 mg
Number of subjects: 0
Study 11421506 — intervention group
Group type: COMPARATOR
Intervention: Placebo Turbuhaler
Number of subjects: 0
Study 9389292 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen challenge (pollen antigens)
Number of subjects: 5
Study 9389292 — intervention group
Group type: COMPARATOR
Intervention: Buffer challenge (diluent)
Number of subjects: 5
Study 7506239 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine gluconate solution irrigation
Number of subjects: 32
Study 7506239 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 32
Study 3030650 — intervention group
Group type: EXPERIMENTAL
Intervention: TFT plus one drop daily of rHu IFN-alpha 2 arg (30 million iu/ml)
Number of subjects: 45
Study 3030650 — intervention group
Group type: EXPERIMENTAL
Intervention: TFT plus rHu IFN-gamma (30 million iu/ml)
Number of subjects: 45
Study 3030650 — intervention group
Group type: EXPERIMENTAL
Intervention: TFT plus a mixture of alpha plus gamma (0.3 million iu/ml each)
Number of subjects: 45
Study 3030650 — intervention group
Group type: EXPERIMENTAL
Intervention: TFT plus a mixture of alpha plus gamma (1.5 million iu/ml each)
Number of subjects: 45
Study 3030650 — intervention group
Group type: COMPARATOR
Intervention: High-titer gamma interferon
Number of subjects: 45
Study 3030650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of alpha plus gamma at a moderate titer (1.5 million iu/ml each)
Number of subjects: 45
Study 3030650 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-titer interferon mixture
Number of subjects: 45
Study 31819304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotics (2x1 starting from the third postoperative day for 30 days, followed by 1x1 for two weeks each month for one year)
Number of subjects: 78
Study 31819304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 78
Study 28956773 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100±53 mg/d)
Number of subjects: 40
Study 28956773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25564551 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation cryoballoon (CB2)
Number of subjects: 360
Study 25564551 — intervention group
Group type: COMPARATOR
Intervention: First-generation cryoballoon (CB1)
Number of subjects: 360
Study 23465535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin plus clarithromycin
Number of subjects: 102
Study 23465535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin plus erythromycin
Number of subjects: 102
Study 23465535 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 102
Study 21977861 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengjing Zhongzi Tang
Number of subjects: 70
Study 21977861 — intervention group
Group type: COMPARATOR
Intervention: Wuzi Yanzong Wan
Number of subjects: 70
Study 18522686 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation (300 mg HMB/kg feed)
Number of subjects: 0
Study 18522686 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented control
Number of subjects: 0
Study 16467546 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 1699
Study 16467546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1699
Study 16467546 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 with alteplase
Number of subjects: 1699
Study 15333385 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with CPB
Number of subjects: 40
Study 15333385 — intervention group
Group type: COMPARATOR
Intervention: CABG without CPB
Number of subjects: 40
Study 15333385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 11212481 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drug regimens
Number of subjects: 210
Study 9334150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoprotein c-erbB-2 expression in breast carcinomas
Number of subjects: 64
Study 9334150 — intervention group
Group type: EXPERIMENTAL
Intervention: Coincidence of c-erbB-2 and tenascin expression
Number of subjects: 64
Study 9334150 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal damage of the basal membrane in intraductal carcinoma
Number of subjects: 64
Study 8323358 — intervention group
Group type: EXPERIMENTAL
Intervention: multinutrient enriched milk
Number of subjects: 31
Study 8323358 — intervention group
Group type: COMPARATOR
Intervention: standard formula
Number of subjects: 31
Study 2942630 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen with codeine (650 mg plus 60 mg every 4 to 6 hours)
Number of subjects: 35
Study 2942630 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (1,000 mg initially then 500 mg twice a day)
Number of subjects: 35
Study 31888765 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometer therapy (IS)
Number of subjects: 50
Study 31888765 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IS therapy)
Number of subjects: 50
Study 29712896 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide and dexamethasone (DRd)
Number of subjects: 0
Study 29712896 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study 27428394 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-view ultrasound
Number of subjects: 260
Study 27428394 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-view ultrasound
Number of subjects: 260
Study 24119064 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel with fluoride and potassium nitrate
Number of subjects: 20
Study 24119064 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide gel without desensitizers
Number of subjects: 20
Study 23062408 — intervention group
Group type: EXPERIMENTAL
Intervention: Xueshuantong Injection (175 mg/d)
Number of subjects: 63
Study 23062408 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 19881333 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant or adjuvant temozolomide (TMZ) with whole-brain irradiation (WBI)
Number of subjects: 280
Study 19881333 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain irradiation (WBI) alone
Number of subjects: 280
Study 19450114 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with bare-metal stents (BMS)
Number of subjects: 0
Study 19450114 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 19450114 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Number of subjects: 0
Study 19450114 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 16208674 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + dietary weight loss
Number of subjects: 316
Study 16208674 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle control
Number of subjects: 316
Study 11489752 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of lycopene twice daily for 3 weeks
Number of subjects: 26
Study 9703292 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg day(-1) for 12 months
Number of subjects: 52
Study 9703292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 52
Study 7978131 — intervention group
Group type: EXPERIMENTAL
Intervention: Belscope blade
Number of subjects: 20
Study 7978131 — intervention group
Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 20
Study 3288871 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy (n = 68)
Number of subjects: 133
Study 3288871 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control group, n = 65)
Number of subjects: 133
Study 3288871 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy (n = 68) among patients with alcoholic and moderately decompensated cirrhosis (Child-Pugh group B)
Number of subjects: 133
Study 3288871 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 133
Study 31987958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated radiation therapy
Number of subjects: 13384
Study 31987958 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing dose per fraction in the experimental arm
Number of subjects: 13384
Study 31987958 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical control at doses above approximately 80 Gy
Number of subjects: 13384
Study 29033152 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine (LB)
Number of subjects: 107
Study 29033152 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine Hydrochloride (HCL)
Number of subjects: 107
Study 26642974 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (0.5 Hz) with figure-8 coil
Number of subjects: 11
Study 26642974 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (0.5 Hz) with round coil
Number of subjects: 11
Study 26642974 — intervention group
Group type: COMPARATOR
Intervention: Sham coil
Number of subjects: 11
Study 24670297 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 583
Study 24670297 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus medroxyprogesterone acetate (CEE + MPA)
Number of subjects: 583
Study 22990464 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Number of subjects: 16
Study 22990464 — intervention group
Group type: COMPARATOR
Intervention: FeSO4
Number of subjects: 16
Study 22990464 — intervention group
Group type: COMPARATOR
Intervention: NaFeEDTA vs FeSO4
Number of subjects: 16
Study 20232750 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria vaccine development
Number of subjects: 300000000
Study 20232750 — intervention group
Group type: COMPARATOR
Intervention: Combination of control measures (e.g., drugs, larvicides, clearing breeding sites)
Number of subjects: 300000000
Study 18452048 — intervention group
Group type: EXPERIMENTAL
Intervention: User-friendly Patient Discharge Form and telephone outreach from a nurse
Number of subjects: 100
Study 18452048 — intervention group
Group type: COMPARATOR
Intervention: Concurrent controls
Number of subjects: 100
Study 18452048 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 100
Study 15714065 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublecortin (DCX) gene expression
Number of subjects: 34
Study 15714065 — intervention group
Group type: COMPARATOR
Intervention: Tyrosine hydroxylase (TH)
Number of subjects: 34
Study 11836040 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy rich diet
Number of subjects: 187
Study 11836040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 187
Study 11836040 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study 11314876 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) for 2 weeks (total of 16,000 stimuli)
Number of subjects: 22
Study 11314876 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study 8646826 — intervention group
Group type: COMPARATOR
Intervention: lamivudine alone
Number of subjects: 14
Study 8646826 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus trimethoprim‐sulfamethoxazole
Number of subjects: 14
Study 1612820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment characteristics predicting abstinence at 6 months
Number of subjects: 0
Study 1612820 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal discomfort and increased frequency of night awakenings during the first month of abstinence
Number of subjects: 0
Study 1612820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendency to 'slip' during Weeks II‐IV
Number of subjects: 0
Study 6376041 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (C.p.)
Number of subjects: 878
Study 6376041 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 878
Study 6376041 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 878
Study 30378768 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioural weight loss treatment (FBT)
Number of subjects: 181
Study 30378768 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing RED (high-energy-dense and low-nutrient-dense) foods and electronics in the home during FBT
Number of subjects: 181
Study 30378768 — intervention group
Group type: COMPARATOR
Intervention: Larger density of public recreation spaces
Number of subjects: 181
Study 29205515 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training (three 1-hour sessions weekly for 1 year)
Number of subjects: 97
Study 29205515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, monitored monthly)
Number of subjects: 97
Study 26768732 — intervention group
Group type: EXPERIMENTAL
Intervention: US commercial cetuximab (Arm A)
Number of subjects: 148
Study 26768732 — intervention group
Group type: COMPARATOR
Intervention: BI-manufactured cetuximab (Arm B)
Number of subjects: 148
Study 24511914 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth programme providing personalised pre‐ and postoperative instructions and tools for recovery
Number of subjects: 215
Study 24511914 — intervention group
Group type: COMPARATOR
Intervention: Control website access
Number of subjects: 215
Study 24511914 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth programme
Number of subjects: 215
Study 22257997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 15
Study 22257997 — intervention group
Group type: COMPARATOR
Intervention: Control (no ethyl chloride spray)
Number of subjects: 15
Study 22257997 — intervention group
Group type: EXPERIMENTAL
Intervention: Before skin preparation
Number of subjects: 15
Study 22257997 — intervention group
Group type: EXPERIMENTAL
Intervention: After skin preparation but before application of ethyl chloride
Number of subjects: 15
Study 21130322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split ramus osteotomy (SSRO)
Number of subjects: 46
Study 21130322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral intraoral vertical ramus osteotomy (IVRO)
Number of subjects: 46
Study 21130322 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal occlusion)
Number of subjects: 46
Study 17651076 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/day soyoligosaccharide intake (LSO)
Number of subjects: 16
Study 17651076 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day soyoligosaccharide intake (HSO)
Number of subjects: 16
Study 16324022 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered at a rate of 20 mg.30 s(‐1) (i.e. 40 mg.min(‐1)) until BIS value reached 35‐45; Group CP required lower dosage of propofol for induction (P = 0.03).
Number of subjects: 40
Study 16324022 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal children); received propofol at the same rate as Group CP.
Number of subjects: 40
Study 11519066 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 at 9 million IU/day subcutaneously for 1 day
Number of subjects: 12
Study 11519066 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 at 9 million IU/day subcutaneously for 2 days
Number of subjects: 12
Study 11519066 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 at 9 million IU/day subcutaneously for 3 days
Number of subjects: 12
Study 11519066 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (22 patients)
Number of subjects: 12
Study 9435364 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution at a rate of 1000 ml/h
Number of subjects: 27
Study 9435364 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution at a rate of 500 ml/h
Number of subjects: 27
Study 8387966 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg twice daily for the first day, followed by 500 mg once daily for four days)
Number of subjects: 107